Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30760989 | 1.00 | L3MBTL1 (0.47) | L3MBTL1RAB9AMAPTNPSR1KDM4E | |
| SCHEMBL19731306 | 0.84 | L3MBTL1 (0.44) | L3MBTL1RAB9AMAPTNPSR1KDM4E | |
| SCHEMBL31377070 | 0.82 | ALDH1A1 (0.43) | KDM4EKMT2AMEN1ALOX15CYP1A2 | |
| SCHEMBL1506544 | 0.82 | ALDH1A1 (0.43) | KDM4EKMT2AMEN1ALOX15CYP1A2 | |
| SCHEMBL10451549 | 0.81 | MEN1 (0.53) | L3MBTL1RAB9AMAPTNPSR1KDM4E | |
| SCHEMBL24313892 | 0.79 | CYP1A2 (0.54) | L3MBTL1MAPTNPSR1KDM4EKMT2A | |
| SCHEMBL29469932 | 0.79 | CYP1A2 (0.54) | L3MBTL1MAPTNPSR1KDM4EKMT2A | |
| SCHEMBL169247 | 0.79 | GAA (0.55) | L3MBTL1RAB9AMAPTNPSR1KDM4E | |
| SCHEMBL10667796 | 0.78 | KIF11 (0.49) | L3MBTL1RAB9AMAPTNPSR1KMT2A | |
| SCHEMBL2130915 | 0.78 | L3MBTL1 (0.49) | L3MBTL1RAB9AMAPTNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140058099-A1 | NOVEL COMPOUND, CHARGE TRANSPORT MATERIAL, AND ORGANIC DEVICE | KYUSHU UNIVERSITY NATIONAL UNIVERSITY CORPORATION (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140058099-A1 | NOVEL COMPOUND, CHARGE TRANSPORT MATERIAL, AND ORGANIC DEVICE | KYUSHU UNIVERSITY NATIONAL UNIVERSITY CORPORATION (JP) | 2014-02-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-6080740-A | Spiro-ketal derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-06-27 | — | — | US | disclosed |
| EP-0880529-A1 | SPIRO-KETAL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030056-A1 | SPIRO-KETAL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | L3MBTL1 2269/4885RAB9A 4272/4885MAPT 3011/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | L3MBTL1 2269/4885RAB9A 4272/4885MAPT 3011/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | L3MBTL1 2269/4885RAB9A 4272/4885MAPT 3011/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | L3MBTL1 2269/4885RAB9A 4272/4885MAPT 3011/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | L3MBTL1 2269/4885RAB9A 4272/4885MAPT 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.